Abstract 60P
Background
A group of spindle cell tumors with characteristic morphologic features and recurrent gene rearrangements has recently been described. Genome-wide DNA methylation profiling has emerged as a powerful tool for both robust classification of known sarcoma entities and identification of novel and clinically relevant subclasses of soft tissue tumors with characteristic alterations.
Methods
Anchored Multiplex polymerase chain reaction amplicons were sequenced on Illumina MiSeq and the data were analyzed using the Archer and Arriba software. Genome-wide DNA methylation profiling was performed using Infinium Methylation EPIC (EPIC) BeadChip (Illumina).
Results
We identified 6 spindle cell sarcoma cases with rearrangement/SNV in BRAF gene, 3 pediatric spindle cell sarcomas with NTRK1 fusion, 1 high-grade sarcoma with ALK fusion and 1 pediatric sarcoma with tyrosine-kinase duplication of EGFR gene. We show that CDKN2A deletion was the most prevalent DNA copy number aberration in spindle cell sarcomas for which this deletion is a typical change and connecting element across different subgroups of spindle cell sarcomas and this change was associated with poor clinical outcome. DNA methylation profiling demonstrated that 5 of our BRAF altered spindle cell sarcomas clustered within MPNST-like methylation class, but methylation analysis classified the next BRAF rearranged case (with CUX1::BRAF fusion) near to angiomatoid fibrous histiocytomas or inflammatory myofibroblastic tumors. Our patients with LMNA::NTRK1 fusion gene clustered within dermatofibrosarcoma protuberans methylation class. Methylation analysis of the sample with ALK fusion did not classify the sample in any of the defined class of methylation classifier.
Conclusions
The current study demonstrates, that all detected rearrangements in our spindle cell cohort are potentially therapeutically targetable. We provide evidence for the pathobiological and epigenetical heterogeneity of spindle cell sarcomas generally, and also of spindle cell sarcomas that shows alteration of the tyrosin-kinase genes.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Ministry of Health, Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague, Czech Republic 00064203.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia
Presenter: Tatyana Abakumova
Session: Cocktail & Poster Display session
Resources:
Abstract